A Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants
Latest Information Update: 07 Jul 2025
At a glance
- Drugs RBD 1119 (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Suzhou Ribo Life Science
Most Recent Events
- 07 Jul 2025 New trial record